Skip to search formSkip to main contentSkip to account menu

XR 5000

Known as: XR5000 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

DACA, acridine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer*
Background. XR5000 is a tricyclic carboxamide-based cytotoxic agent that binds to DNA by intercalation and stimulates DNA… 
Review
2003
Review
2003
Chemosensitivity testing as an aid to anti-cancer drug and regimen development.
  • I. Cree
  • Recent results in cancer research. Fortschritte…
  • 2003
  • Corpus ID: 24896844
The ATP-based chemosensitivity assay has proved particularly useful for the evaluation of new anti-cancer agents and combinations… 
Review
2003
Review
2003
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.
2002
2002
Phase II study of XR 5000 ( DACA ) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme
*Correspondence to: Dr C. Twelves, Cancer Research Campaign Department of Medical Oncology, CRC Beatson Laboratories, Alexander… 
2000
2000
An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)